Latest News

Only one in 10 million babies are born with the rare disease that this Hounslow toddler battles with. His genetic liver condition means calcium crystals build up in Archie’s body and without a liver transplant the illness can be fatal. Archie’s life was saved by his mum, who donated a...
Preparations are taking place for a family fun day which will be held in Montrose later this summer. The Over the Rainbow event is being planned as a final fling outdoors for families on Sunday, September 6 and as a commemoration of Montrose’s “butterfly girl” Adana Forsyth. The day has...
After weeks of planning, the fund-raising walk for Bridger Gustafson will take place this Saturday, June 13, at Constitution Park in Lovell. The fun-for-the-family event will take place at 7 a.m. Bridger, the 5-year-old son of Blake and JanaLee Moncur Gustafson of Carrollton, Texas, and the grandson of Brent and...
After five of his seven siblings were diagnosed with Huntington’s disease (HD) in the past seven years, Robert Robinson and his wife, Laura, sprang to action. In an energetic quest, they became involved in the P.E.I. Chapter of Huntington Society of Canada and attended a national conference in Charlottetown last...
When Lisa Doo planned a yard sale last year to benefit research for Moyamoya disease, of which her son Justin is stricken, most folks in the Walpole area had never heard of the disease. Now, with another sale planned for Saturday, more residents are aware of Justin’s case, but Lisa...
TURKU, Finland and BOSTON, Mass. — Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announced that the first patient has been dosed in Phase 2 of the BEXMAB trial that evaluates the...
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM:FARN, First North:FARON), a clinical-stage biopharmaceutical company, today announced updated full data from its Phase 1/2 BEXMAB study, presented at the American Society of Hematology (ASH) 2025 Annual Meeting (oral and poster presentation). The data highlights significant improvement in survival outcome and new findings on...